BioCentury
ARTICLE | Finance

Platform Twist

Why crossover investors flocked to DNA synthesis company Twist's series D

January 25, 2016 8:00 AM UTC

Backers of Twist Bioscience Corp. believe the DNA synthesis company can grow to be the next Illumina Inc. (NASDAQ:ILMN). They might not have to wait long to see whether the public markets agree, as last week's $61 million series D round is expected to be Twist's final private financing.

Crossover backers Arch Overage Fund, Merieux Developpement, Cormorant, Fidelity and Foresite joined Arch Venture Partners, WuXi Healthcare Ventures, Illumina, Tao Invest, Paladin Capital, Yuri Milner, Boris Nikolic and additional strategic and venture investors in the round. ...